Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection

Chi‐Jen Chu, Munira Hussain, Anna S. F. Lok – 7 March 2007 – The goals of this retrospective study were to determine whether there is a threshold hepatitis B virus (HBV) DNA value associated with spontaneous or antiviral therapy—related hepatitis B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value that can be used for differentiating inactive carriers from patients with HBeAg‐negative chronic hepatitis B.

Interleukin 1β inhibits CAR‐induced expression of hepatic genes involved in drug and bilirubin clearance

Eric Assenat, Sabine Gerbal‐Chaloin, Dominique Larrey, Jean Saric, Jean‐Michel Fabre, Patrick Maurel, Marie‐José Vilarem, Jean Marc Pascussi – 7 March 2007 – During the inflammatory response, intrahepatic cholestasis and decreased drug metabolism are frequently observed.

Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine

Dr. Vito Di Marco, Alfredo Marzano, Pietro Lampertico, Pietro Andreone, Teresa Santantonio, Piero Luigi Almasio, Mario Rizzetto, Antonio Craxì – 7 March 2007 – The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)‐negative chronic hepatitis is unclear. In a retrospective multicenter study, we have analyzed the virological events observed during lamivudine therapy in patients with HBeAg‐negative chronic hepatitis and evaluated the correlation between virological response and clinical outcomes.

Induction or expansion of T‐cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

Maryline Mancini‐Bourgine, Hélène Fontaine, Daniel Scott‐Algara, Stanislas Pol, Christian Bréchot, Marie‐Louise Michel – 7 March 2007 – Despite the availability of effective hepatitis B vaccines for many years, over 370 million people remain persistently infected with hepatitis B virus (HBV). Viral persistence is thought to be related to poor HBV‐specific T‐cell responses. A phase I clinical trial was performed in chronic HBV carriers to investigate whether HBV DNA vaccination could restore T‐cell responsiveness.

T2 hyperintensity along the cortico‐spinal tract in cirrhosis relates to functional abnormalities

Juan Córdoba, Nuria Raguer, Montserrat Flavià, Víctor Vargas, Carlos Jacas, Juli Alonso, Alex Rovira – 7 March 2007 – Magnetic resonance has shown T2 hyperintensity along the cortico‐spinal tract in the brain of cirrhotic patients. This abnormality, which is reversible after liver transplantation, appears to correspond to mild edema. Because astrocytic edema present in hepatic encephalopathy may be responsible for neuronal dysfunction, we studied whether T2 hyperintensity along the cortico‐spinal tract may relate to functional abnormalities.

Subscribe to